Trial Profile
Phase I Study of Escalating-Doses of Bendamustine for Patients With Previously Treated Multiple Myeloma
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 24 Oct 2016
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 19 Oct 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 16 Dec 2014 New trial record